AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03102723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cangrelor
Description: 1. Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~   Or~2. Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI.
Study NCT03372200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Oral daily dosing for 14 weeks
Study NCT03372200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Oral daily dosing for 14 weeks
Study NCT01744652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group.
Study NCT01744652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle.
Study NCT03154008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
Study NCT01522417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short Tirofiban
Description: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
Study NCT01522417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptifibatide
Description: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
Study NCT01522417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long Tirofiban
Description: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.
Study NCT00450411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 125-Iodine
Description: Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
Study NCT00450411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 103-palladium
Description: Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
Study NCT04656834 — intervention group
Intervention type: PROCEDURE
Intervention: hand incision closure using monocryl sutures and skin glue
Description: At the end of surgery, the investigator will close the incision using monocryl sutures and skin glue
Study NCT04656834 — intervention group
Intervention type: PROCEDURE
Intervention: hand incision closure using simple nylon sutures
Description: At the end of surgery, the investigator will close the incision using simple nylon sutures
Study NCT03105310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa
Description: Pegylated interferon alfa
Study NCT03105310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa
Description: Pegylated interferon alfa
Study NCT03105310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe
Study NCT04999813 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive intensive intervention
Description: * Health education ② Medication guidance: antihypertensive therapy, hypoglycemic therapy, lipid-lowering therapy~  * Diet guidance: A healthy diet requires low-salt, low-oil, more fruits and vegetables, more cellulose, appropriate amount of protein, restricted fat and cholesterol foods, etc. Quit smoking, drink less alcohol, and limit alcohol intake.~    * Exercise guidance: Do aerobic exercises of medium and low intensity at least 5 times a week, and exercise for at least 30 minutes each time.~      * Weight loss guidance.
Study NCT01417026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin (Trade name: Syntocinon)
Description: This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
Study NCT01417026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin (Trade name: Syntocinon)
Description: This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
Study NCT03686046 — intervention group
Intervention type: OTHER
Intervention: Exploratory use
Description: Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
Study NCT01918735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control matched to the oral or intravenous experimental comparator drug
Study NCT01918735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006
Description: Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects.
Study NCT01037348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5mg
Study NCT01751828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT02808364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
Study NCT03519854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
Study NCT04135469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral for tax preparation services
Description: Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
Study NCT04135469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for tax preparation services
Description: Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
Study NCT04135469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigator assisted tax preparation services at BMC
Description: A study navigator will assist the participant in accessing the BMC located tax preparation services.
Study NCT03519854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
Study NCT03519854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmeron®
Description: Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study NCT03519854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron®
Description: Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study NCT00416182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme (dornase alfa)
Description: 2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
Study NCT00416182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.5 mL of placebo delivered via Sinustar nebulizer device
Study NCT03352791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSM-H Hospice Edition performance improvement program
Description: Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
Study NCT03352791 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: control will receive usual care from a care team who has not received the performance improvement program.
Study NCT01567384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906 and Pemetrexed
Description: Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1.
Study NCT03832595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR-based PHM
Description: An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology).
Study NCT03832595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
Study NCT00803452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: Oral doxycycline 100mg bid
Study NCT00803452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: topical 1% azithromycin daily to eye
Study NCT01818479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplant
Description: Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
Study NCT01818479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Study NCT02115880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention programme
Description: Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
Study NCT01338025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART regimen
Description: The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
Study NCT01338025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC or FTC monotherapy
Description: The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
Study NCT01427231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: glucose
Description: The effect of a glucose solution on cognitive performance will be measured.
Study NCT01427231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sacharose
Description: The effect of a sacharose solution on cognitive performance will be measured.
Study NCT00636649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg
Study NCT00636649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06723873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping
Description: The treatment group received Kinesiology Taping around the trunk extensors, lower and middle trapezius, supraspinatus, deltoid muscle group, and serratus anterior muscle.
Study NCT06723873 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Kinesio Taping
Description: In the control group, kinesiology tape was applied without tension and in a manner that did not target specific muscle groups or respect the anatomical origin and insertion points.
Study NCT06733961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SCUBE-1 and VAP-1
Description: There is no other study comparing these biomarkers with healthy volunteers in the diagnosis of pulmonary embolism.
Study NCT01464164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks
Study NCT01464164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept with prednisone boost
Description: Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg).
Study NCT02529046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CLA
Description: CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
Study NCT02529046 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group received 4 g/day of olive oil. Aerobic exercise
Study NCT01427231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effect of a placebo drink with sweeteners on cognitive performance will be measured.
Study NCT01631799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral catheter
Description: Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
Study NCT01631799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter
Description: The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
Study NCT02800135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
Study NCT01808781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises plus walking program
Description: Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention.
Study NCT01808781 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking only program
Description: Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
Study NCT02412163 — intervention group
Intervention type: DEVICE
Intervention: Ellipse IM HTO Nail
Study NCT02650401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entrectinib
Description: TRKA/B/C, ROS1, and ALK inhibitor
Study NCT04487093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoantigen vaccine + EGFR-TKI
Description: Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.~The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance.
Study NCT04487093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoantigen vaccine + anti-angioge
Description: neoantigen vaccine + anti-angioge
Study NCT03872921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norUrsodeoxycholic Acid
Description: oral treatment
Study NCT03872921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norUrsodeoxycholic Acid
Description: oral treatment
Study NCT00808379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
Study NCT00808379 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Additional Radiation boost to the primary tumor volume
Description: 15-20Gy
Study NCT04133155 — intervention group
Intervention type: DRUG
Intervention: nab paclitaxel plus gemcitabine
Description: Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
Study NCT04081467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: 10-day of complete bed rest
Study NCT04450264 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: African Immigrant Breast Cancer Education Program
Description: African immigrant women are at significant risk for not participating in preventive screening, such as for breast cancer. Thus, this project will culturally adapt an existing evidenced-based, the Witness Project, by identifying potential barriers and guided by the Health Belief Model incorporate those findings into a group-based narrative education program for English and French-speaking African immigrant women. The program content will include: (1) information about the benefits of early detection of breast cancer screening, (2) education about disparities in breast cancer, (3) disparities in breast cancer screening among African immigrant women, and (4) will address the unique barriers and facilitators of African immigrant women identified in Aim 1 of this study. The program will use a culturally matched peer approach to educate and model successful experiences with mammography screening.
Study NCT01738984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomZing Web Program
Description: Online web platform that is accessed via a television connected to internet
Study NCT01738984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise DVD
Description: Standard exercise DVD that demonstrates exercises a women does with an infant.
Study NCT02306070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin treatment + standard of care dietary and exercise advice
Study NCT02306070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No metformin treatment
Description: no metformin treatment + standard of care dietary and exercise advice